Direct Thrombin Inhibitors
Direct Thrombin Inhibitors
复制标题
DOI：
10.1177/1074248410395941
复制
发表时间：
2012-03
影响因子：
2.6
通讯作者：
P. J. O'Brien;L. Mureebe
中科院分区：
文献类型：
--
作者：
P. J. O'Brien;L. Mureebe
心血管疾病是导致死亡的主要原因，病理性凝血在心血管疾病的发展、传播和干预中起着不可或缺的作用。肝素和维生素K拮抗剂这两种经典的抗凝剂，虽然已经为人类服务了近世纪，但都是不方便和非特异性的。凝血酶通过直接和间接的作用对凝血起重要作用，是病理性血栓形成的一个非常有吸引力的药物干预靶点。本文将回顾直接凝血酶抑制剂的性质，目前的适应症，和正在进行的试验。
Cardiovascular disease is a leading cause of death and pathologic coagulation plays an integral role in the development, propagation, and intervention of cardiovascular disease. The 2 classic anticoagulants, heparin and vitamin K antagonists, though having served humanity for nearly a century, are both inconvenient and nonspecific. Through both direct and indirect roles, thrombin is essential to coagulation, and makes for a very attractive target in medical intervention of pathologic thrombosis. This article will review the nature of direct thrombin inhibitors, current indications, and ongoing trials.